Wells Fargo Initiates Coverage On Axsome Therapeutics with Overweight Rating, Announces Price Target of $140
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on Axsome Therapeutics with an Overweight rating and set a price target of $140.
September 03, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has initiated coverage on Axsome Therapeutics with an Overweight rating and a price target of $140, indicating a positive outlook.
The initiation of coverage with an Overweight rating and a high price target by a major financial institution like Wells Fargo is likely to boost investor confidence and positively impact the stock price of Axsome Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100